

Special Issue

Vaccine Equity and Immunization Program Evaluation

Message from the Guest Editors

Establishing a new vaccination program requires a commitment to equity. It is crucial to develop strategies that reach high-priority groups, such as healthcare workers or highly susceptible members of the population like older or immunocompromised individuals. It is equally important to ensure that vaccination is available to all sections of the community, including socio-economic and minority groups that have proven harder to reach in the past. Achieving this may require new engagement strategies, such as tailored community engagement plans, to communicate the vaccination's benefits and risks effectively. Both domestic and international funding should be coordinated and delivered to support these efforts. Finally, evaluating the vaccination program is imperative to demonstrate its value, ensure accountability, and learn lessons for the future. This Special Issue welcomes scholars who are working on developing, implementing, or evaluating new immunization programs, with a focus on vaccine equity, to submit their work. The deadline for submissions is August 2024.

Guest Editors

Dr. Mounia Hocine

Conservatoire National des Arts et Metiersdisabled, Paris, France

Dr. Mahmoud Zureik

EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance, 93285 Saint-Denis, Cedex, France

Deadline for manuscript submissions

closed (31 August 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/191467

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).